Context Therapeutics Inc. (CNTX) Stock

Context Therapeutics Inc. (CNTX) is a Healthcare stock trading at $0.63 (as of 2026-06-18), with a market capitalization of $261.86M and a trailing P/E of -1.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies for women in the United States. Its pipeline includes onapristone extended release (ONA-XR) and CLDN6xCD3, an anti-CD3 x anti-claudin 6 bispecific antibody, and it also has a collaboration and licensing arrangement with Integral Molecular for an anti-claudin 6 bispecific monoclonal antibody in gynecologic cancer.

Valuation — source: SEC EDGAR (first-party)
Price	$0.63
Market Cap	$261.86M
P/E Ratio	-1.5
EV / EBITDA	-0.1
Price / Book	1.14
Price / Sales	20.32
DCF Value (model)	$-4.18
DCF Upside vs Price	-768.3%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$3.38M
Net Margin	-1069.2%
Return on Equity	-77.1%
Current Ratio	8.96
Revenue Growth (YoY)	5.6%
EPS Growth (YoY)	-17.4%
FCF Growth (YoY)	81.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	0.82 (distress)

Valuation vs Sector & Industry
Stock P/E	-1.5
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-107.4%
vs Industry	-109.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	MPM BIOIMPACT LLC ($27.98M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Martin A. Lehr
Employees	12
Country	US
IPO Date	2021-10-20

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.